This immersive exhibition is being held, where Roche's innovative drugs make lymphoma diagnosis and treatment a promising future
The increasing application of innovative drugs and cell therapy is making clinical cure possible for lymphoma patients. On the occasion of the 20th World Lymphoma Awareness Day, the immersive lymphoma light and shadow science exhibition "Born of Beauty, Sailing towards the Vast Life" was launched in Shanghai.
This science popularization exhibition is jointly organized by Lymphoma Home and Pudong multinational company Roche Pharmaceuticals China. As the first immersive light and shadow science popularization exhibition on lymphoma in China, the organizer stated that this exhibition will lead the audience into the micro world of the human body, explore the mysteries of life and the past and present of lymphoma diagnosis and treatment, convey the information that lymphoma can be cured through standardized diagnosis and treatment, and showcase the spirit of doctors and patients working together to fight against lymphoma to society.
Enable the public to establish standardized diagnosis and treatment concepts
Lymphoma, known as "thousand face tumor", is one of the most common hematological malignancies in China. The incidence rate of malignancies ranks eighth in China, with about 100000 new lymphoma patients every year. Among them, it can be divided into Hodgkin's lymphoma and non Hodgkin's lymphoma according to the pathological type. Among non Hodgkin's lymphoma, diffuse large B-cell lymphoma and follicular lymphoma are the most common.
Diffuse large B-cell lymphoma is the most aggressive malignant lymphoma with the highest incidence rate, accounting for about 35% to 40% of non Hodgkin's lymphoma. Compared with other lymphoid system tumors, the prognosis is poor, and about 40% to 50% of patients still have the risk of recurrence after first-line treatment. Follicular lymphoma is also one of the B-cell lymphoma with high incidence rate in China, which has the characteristics of recurrent and refractory disease.
In this exhibition, an immersive light and shadow experience will lead the audience into the micro environment of the human body. Through various light and shadow effects, the audience will be immersed in the human blood and lymphatic tissue, witnessing the occurrence of various types of lymphoma caused by B cell mutations, as well as the various impacts of lymphoma on the human body.
![This immersive exhibition is being held, where Roche's innovative drugs make lymphoma diagnosis and treatment a promising future](https://a5qu.com/upload/images/f3ce79f45f8c9a555f44b6cc9368f834.jpg)
"The treatment and life of lymphoma patients after getting sick is actually like exploring the unknown in the universe," said Gu Hongfei, founder of Lymphoma Home. "This exhibition uses a new perspective and language to educate the public about lymphoma disease knowledge and establish the concept of standardized diagnosis and treatment. As a former lymphoma patient, we have witnessed the continuous changes in lymphoma treatment plans, and countless lymphoma patients like us have benefited from it."
For lymphoma patients, in recent years, with the increase of innovative drugs, the possibility of "cure" has also been constantly increasing. Professor Niu Ting from West China Hospital of Sichuan University said, "It is World Lymphoma Day again, and I hope to continue the power of care. In the future, we can see more and more lymphoma patients actively fighting against the disease and bravely pursuing the infinite possibilities of life."
While innovative drugs are increasing year by year, standardized treatments such as referral and treatment are gradually being improved. Professor Bai Ou from the Norman Bethune First Hospital of Jilin University said, "Currently, we are pleased to see that some hospitals with higher levels of lymphoma treatment have begun to explore individual case management systems for lymphoma patients. They are not only responsible for educating lymphoma patients in the hospital, but also exploring ways to help patients connect with follow-up and referral after discharge."
Roche's two innovative drugs are being brought to China as soon as possible
In recent years, the introduction of innovative drugs and the iteration of standardized treatment plans have significantly improved the overall survival status of lymphoma patients in China. Lymphoma has become one of the tumors with high control and cure rates. In this exhibition, an immersive display of the history of human struggle against lymphoma was also systematically presented, allowing the audience to experience firsthand how different treatment methods, including radiotherapy, chemotherapy, targeting, cell therapy, and immunity, can inhibit the growth of lymphoma.
Professor Ma Jun, Director of Harbin Institute of Hematology and Oncology, introduced: "Humans have been exploring effective treatment options for lymphoma, from the earliest nitrogen mustard era to the emergence of the first biological monoclonal antibody CD20, to antibody conjugates like CD79b, as well as the recent development of bispecific antibodies that can simultaneously target CD20 and CD3, and even the application of advanced technologies such as bone marrow transplantation and cell therapy. More and more innovative drugs and cell therapy are making clinical cure possible for lymphoma patients."
![This immersive exhibition is being held, where Roche's innovative drugs make lymphoma diagnosis and treatment a promising future](https://a5qu.com/upload/images/6b49b808235fce05d18c21e58a88ccd7.jpg)
"In recent years, China has vigorously built a multi-level medical security system, and many innovative drugs have entered the national medical insurance drug catalog through national medical insurance negotiations shortly after being approved. For example, octuzumab entered the medical insurance in the year of approval, greatly reducing the burden on patients. At the same time, many innovative drugs are also continuously improving the accessibility of innovative drugs to lymphoma patients through social and commercial insurance, welfare insurance, and medical charity projects." said Professor Wu Depei from the First Affiliated Hospital of Suzhou University.
The reporter learned from the event that as a joint supporter of this science popularization exhibition, Roche, which has been deeply involved in the field of blood diseases for more than 30 years, is also accelerating the pace of introducing innovative drugs in China.
Roche Pharmaceuticals China President Bian Xin said, "Roche has a rich product pipeline, and in the past two years, we have continuously introduced innovative lymphoma products into China, benefiting Chinese lymphoma patients. In the near future, we also hope to bring two innovative bispecific antibody innovative drugs that can simultaneously target CD20/CD3 to China as soon as possible. While continuously bringing innovative drugs to China, we are also actively working closely with all sectors of society to explore and build a comprehensive care system for lymphoma patients, committed to helping more lymphoma patients prolong their lives, improve their quality of life, and strive to achieve the ultimate goal of cure."
Text: Yang Zhenying
Official WeChat from Pudong